Wall Street brokerages predict that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will post ($1.03) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Alder Biopharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.36) and the highest estimate coming in at ($0.88). Alder Biopharmaceuticals posted earnings of ($0.80) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 28.8%. The business is scheduled to issue its next earnings report on Monday, February 25th.

According to Zacks, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.59) per share for the current financial year, with EPS estimates ranging from ($5.04) to ($4.25). For the next year, analysts forecast that the firm will post earnings of ($3.45) per share, with EPS estimates ranging from ($5.45) to ($1.73). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Alder Biopharmaceuticals.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.22.

A number of research analysts recently commented on ALDR shares. ValuEngine downgraded shares of Alder Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 24th. Zacks Investment Research raised shares of Alder Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Monday, August 20th. Canaccord Genuity boosted their price objective on shares of Alder Biopharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. BMO Capital Markets boosted their price objective on shares of Alder Biopharmaceuticals from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, Stifel Nicolaus started coverage on shares of Alder Biopharmaceuticals in a research report on Tuesday, August 7th. They set a “buy” rating and a $30.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. Alder Biopharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $21.67.

In other Alder Biopharmaceuticals news, insider John A. Latham sold 24,999 shares of Alder Biopharmaceuticals stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $17.99, for a total value of $449,732.01. Following the completion of the sale, the insider now directly owns 268,692 shares in the company, valued at $4,833,769.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey T. L. Smith sold 5,040 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $18.00, for a total transaction of $90,720.00. Following the completion of the sale, the director now owns 5,871 shares of the company’s stock, valued at $105,678. The disclosure for this sale can be found here. Insiders have sold 90,120 shares of company stock worth $1,407,922 over the last ninety days. 17.40% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of ALDR. SG Americas Securities LLC acquired a new stake in shares of Alder Biopharmaceuticals in the second quarter worth $107,000. Pacer Advisors Inc. acquired a new stake in shares of Alder Biopharmaceuticals in the third quarter worth $118,000. Tower Research Capital LLC TRC acquired a new stake in shares of Alder Biopharmaceuticals in the second quarter worth $128,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Alder Biopharmaceuticals in the first quarter worth $142,000. Finally, LPL Financial LLC acquired a new stake in shares of Alder Biopharmaceuticals in the first quarter worth $156,000. Institutional investors and hedge funds own 98.86% of the company’s stock.

Alder Biopharmaceuticals stock opened at $12.72 on Friday. The company has a market capitalization of $869.80 million, a PE ratio of -2.57 and a beta of 2.70. The company has a current ratio of 15.34, a quick ratio of 15.34 and a debt-to-equity ratio of 0.97. Alder Biopharmaceuticals has a fifty-two week low of $10.05 and a fifty-two week high of $20.87.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Featured Story: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Alder Biopharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.